TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY

被引：20

作者：

Manns, M. ^{[1
]}

Muir, A. ^{[2
]}

Adda, N. ^{[3
]}

Jacobson, I. ^{[4
]}

Afdhal, N. ^{[5
]}

Heathcote, J. ^{[6
]}

Zeuzem, S. ^{[7
]}

Reesink, H. ^{[8
]}

Terrault, N. ^{[9
]}

Bsharat, M. ^{[3
]}

George, S. ^{[3
]}

McHutchison, J. ^{[2
]}

Di Bisceglie, A. ^{[10
]}

机构：

[1] Hannover Med Sch, D-3000 Hannover, Germany

[2] Duke Univ, Med Ctr, Durham, NC 27706 USA

[3] Vertex Pharmaceut, Cambridge, MA USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA

[6] Univ Toronto, Toronto, ON, Canada

[7] Univ Frankfurt, Frankfurt, Germany

[8] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

[10] St Louis Univ, Sch Med, St Louis, MO USA

来源：

JOURNAL OF HEPATOLOGY | 2009年 / 50卷

关键词：

D O I：

10.1016/S0168-8278(09)61046-1

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1044

引用

页码：S379 / S379

页数：1

共 50 条

[1] SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy
Di Bisceglie, Adrian M.
Muir, Andrew M. J.
Adda, Nathalie
Jacobson, Ira M.
Afdhal, Nezam H.
Heathcote, E. Jenny
Zeuzem, Stefan
Reesink, Henk W.
Terrault, Norah
Bsharat, Mohammad
George, Shelley
Manns, Michael P.
McHutchison, John
GASTROENTEROLOGY, 2009, 136 (05) : A116 - A116
[2] PROVE3 FINAL RESULTS AND 1-YEAR DURABILITY OF SVR WITH TELAPREVIR-BASED REGIMEN IN HEPATITIS C GENOTYPE 1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY
McHutchison, John G.
Manns, Michael P.
Muir, Andrew
Terrault, Norah
Jacobson, Ira M.
Afdhal, Nezam H.
Heathcote, E. Jenny
Zeuzem, Stefan
Reesink, Hendrik W.
Bsharat, Mohammad
George, Shelley
Adda, Nathalie
Di Bisceglie, Adrian M.
HEPATOLOGY, 2009, 50 (04) : 334A - 335A
[3] A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS
McHutchison, John G.
Shiffman, Mitchell L.
Terrault, Norah
Manns, Michael P.
Di Bisceglie, Adrian M.
Jacobson, Ira M.
Afdhal, Nezom H.
Heathcote, E. Jenny
Zeuzem, Stefan
Reesink, Hendrik W.
George, Shelley
Adda, Nathalie
Muir, Andrew J.
HEPATOLOGY, 2008, 48 (04) : 431A - 432A
[4] A STUDY OF TELAPREVIR COMBINED WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN SUBJECTS WITH WELL-DOCUMENTED NON-RESPONSE OR RELAPSE AFTER PREVIOUS PEGINTERFERON-ALFA-2A AND RIBAVIRIN TREATMENT: INTERIM ANALYSIS
Shiffman, Mitchell L.
Berg, Thomas
Poordad, F. Fred
Bronowicki, Jean-Pierre
Muir, Andrew J.
Gordon, Stuart C.
George, Shelley
Adda, Nathalie
McHutchison, John G.
HEPATOLOGY, 2008, 48 (04) : 1135A - 1136A
[5] TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C: FINAL RESULTS OF THE PROVE2 STUDY
Zeuzem, Stefan
Hezode, Chritophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Alves, Katia
Bengtsson, Leif
Gharakhanian, Shahin
Kauffman, Robert
Alam, John J.
Pawlotsky, Jean-Michel
HEPATOLOGY, 2008, 48 (04) : 418A - 419A
[6] SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR
Berg, T.
McHutchison, J. G.
Adda, N.
Poordad, F.
Shiffman, M. L.
Ferenci, P.
Heathcote, J.
Pawlotsky, J. -M.
Zeuzem, S.
Reesink, H.
Dusheiko, G.
Martin, E.
Alexanderian, D.
George, S.
Muir, A. J.
JOURNAL OF HEPATOLOGY, 2010, 52 : S2 - S2
[7] The role of cholesterol on sustained virological response (SVR) in the treatment of genotype-1 infected hepatitis C (CHC) patients with peginterferon-alfa-2a (PEG) and ribavirin (RBV)
Mauss, S.
Zehnter, E.
Hueppe, D.
Kaiser, K.
Boeker, K.
Lutz, T.
Heyne, R.
John, C.
Moog, G.
Schober, A.
Pfaff, R.
Zipf, A.
Racky, S.
Lohmeyer, J.
Bokemeyer, B.
Kallinowski, B.
Witthoeft, T.
Alshuth, U.
JOURNAL OF HEPATOLOGY, 2008, 48 : S304 - S304
[8] Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Tran, Albert
Grange, Jean-Didier
Mathurin, Philippe
Schmidt, Wolfgang E.
Diepolder, Helmut
Marcellin, Patrick
Wedemeyer, Heiner
Forestier, Nicole
Mangels, Wendy
Gharakhanian, Shahin
Kauffman, Robert S.
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
GASTROENTEROLOGY, 2008, 134 (04) : A755 - A755
[9] Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naive Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE 1, PROVE2, PROVE3 and Study 107
Shiffman, Mitchell
Berg, Thomas
Muir, Andrew
McHutchison, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
Bengtsson, Leif
Adda, Nathalie
George, Shelley
Kauffman, Robert
Poordad, Fred
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S102 - S102
[10] Response-guided Telaprevir Combination Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Peginterferon Alfa-2a/Ribavirin
Muir, Andrew
Adiwijaya, Bambang
Poordad, Fred
Gritz, Linda
Bengtsson, Leif
Luo, Don
Picchio, Gaston
Kauffman, Robert
Adda, Nathalie
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S114 - S115

← 1 2 3 4 5 →